These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1714449)

  • 21. Conformational and amino acid residue requirements for the saposin C neuritogenic effect.
    Qi X; Kondoh K; Krusling D; Kelso GJ; Leonova T; Grabowski GA
    Biochemistry; 1999 May; 38(19):6284-91. PubMed ID: 10320358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of activators and inhibitors to define the properties of the active site of normal and Gaucher disease lysosomal beta-glucosidase.
    Gatt S; Dinur T; Osiecki K; Desnick RJ; Grabowski GA
    Enzyme; 1985; 33(2):109-19. PubMed ID: 3924590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human acid beta-glucosidase: use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites.
    Osiecki-Newman K; Fabbro D; Legler G; Desnick RJ; Grabowski GA
    Biochim Biophys Acta; 1987 Sep; 915(1):87-100. PubMed ID: 2956992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Saposin C induces pH-dependent destabilization and fusion of phosphatidylserine-containing vesicles.
    Vaccaro AM; Tatti M; Ciaffoni F; Salvioli R; Serafino A; Barca A
    FEBS Lett; 1994 Aug; 349(2):181-6. PubMed ID: 8050562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural analysis of saposin C and B. Complete localization of disulfide bridges.
    Vaccaro AM; Salvioli R; Barca A; Tatti M; Ciaffoni F; Maras B; Siciliano R; Zappacosta F; Amoresano A; Pucci P
    J Biol Chem; 1995 Apr; 270(17):9953-60. PubMed ID: 7730378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease.
    Sun Y; Liou B; Chu Z; Fannin V; Blackwood R; Peng Y; Grabowski GA; Davis HW; Qi X
    EBioMedicine; 2020 May; 55():102735. PubMed ID: 32279952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.
    Romero R; Ramanathan A; Yuen T; Bhowmik D; Mathew M; Munshi LB; Javaid S; Bloch M; Lizneva D; Rahimova A; Khan A; Taneja C; Kim SM; Sun L; New MI; Haider S; Zaidi M
    Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5086-5095. PubMed ID: 30808805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneity in human acid beta-glucosidase revealed by cellulose-acetate electrophoresis.
    Sa Miranda MC; Aerts JM; Pinto RA; Magalhaes JA; Barranger JA; Tager JM; Schram AW
    Biochim Biophys Acta; 1988 May; 965(2-3):163-8. PubMed ID: 3130106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse.
    Sun Y; Ran H; Zamzow M; Kitatani K; Skelton MR; Williams MT; Vorhees CV; Witte DP; Hannun YA; Grabowski GA
    Hum Mol Genet; 2010 Feb; 19(4):634-47. PubMed ID: 20015957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulation of acid ceramidase activity by saposin D.
    Azuma N; O'Brien JS; Moser HW; Kishimoto Y
    Arch Biochem Biophys; 1994 Jun; 311(2):354-7. PubMed ID: 8203897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human acid beta-glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes.
    Grabowski GA; Osiecki-Newman K; Dinur T; Fabbro D; Legler G; Gatt S; Desnick RJ
    J Biol Chem; 1986 Jun; 261(18):8263-9. PubMed ID: 3087971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gaucher disease: a membranous enzymopathy.
    Desnick RJ; Grabowski GA; Dinur T; Fabbro D; Goldblatt J; Gatt S
    Prog Clin Biol Res; 1982; 97():193-215. PubMed ID: 6818558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of human saposin B sphingolipid-binding specificity by alternative splicing. A study with saposin B-derived synthetic peptides.
    Lamontagne S; Potier M
    J Biol Chem; 1994 Aug; 269(32):20528-32. PubMed ID: 8051151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analyses of catalytic activity and inhibitor binding of human acid beta-glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations.
    Grace ME; Graves PN; Smith FI; Grabowski GA
    J Biol Chem; 1990 Apr; 265(12):6827-35. PubMed ID: 2324100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saposin A: second cerebrosidase activator protein.
    Morimoto S; Martin BM; Yamamoto Y; Kretz KA; O'Brien JS; Kishimoto Y
    Proc Natl Acad Sci U S A; 1989 May; 86(9):3389-93. PubMed ID: 2717620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease.
    Premkumar L; Sawkar AR; Boldin-Adamsky S; Toker L; Silman I; Kelly JW; Futerman AH; Sussman JL
    J Biol Chem; 2005 Jun; 280(25):23815-9. PubMed ID: 15817452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human acid beta-glucosidase: use of sphingosyl and N-alkyl-glucosylamine inhibitors to investigate the properties of the active site.
    Greenberg P; Merrill AH; Liotta DC; Grabowski GA
    Biochim Biophys Acta; 1990 May; 1039(1):12-20. PubMed ID: 2141287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Saposins (sphingolipid activator proteins) in the twitcher mutant mouse.
    Shigematsu H; Morimoto S; Kishimoto Y; Weiler S; Tomich J; Barranger J; Shinohara M; Yeager AM; O'Brien JS
    J Neurochem; 1990 Nov; 55(5):1659-62. PubMed ID: 2120388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human acid beta-glucosidase: inhibition studies using glucose analogues and pH variation to characterize the normal and Gaucher disease glycon binding sites.
    Osiecki-Newman K; Legler G; Grace M; Dinur T; Gatt S; Desnick RJ; Grabowski GA
    Enzyme; 1988; 40(4):173-88. PubMed ID: 3234317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of GM1-ganglioside to a synthetic peptide derived from the lysosomal sphingolipid-activator-protein saposin B.
    Champagne MJ; Lamontagne S; Potier M
    FEBS Lett; 1994 Jun; 347(2-3):265-7. PubMed ID: 8034015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.